Unicycive Therapeutics, Inc. Stock Analysis & AI Score
Unicycive Therapeutics, Inc. (UNCY) has an ST Score of 40.5 (C), driven by its Forecast (A) and held back by its Sentiment (F). Analysts rate it Buy with a $22.00 price target (+357.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Unicycive Therapeutics, Inc. (UNCY) has an ST Score of 40.5 (C), driven by its Forecast (A) and held back by its Sentiment (F). Analysts rate it Buy with a $22.00 price target (+357.4% upside).
- Strongest
- ForecastA
- Weakest
- SentimentF
All factor grades
- ForecastA
- ValuationB+
- Financial StrengthC+
- GrowthC
- ProfitabilityC-
- MomentumC-
- SentimentF
- Piotroski2/9
Contact
UNCY stock: frequently asked questions
What is UNCY's ST Score?
Unicycive Therapeutics, Inc. (UNCY) has an ST Score of 40.5 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is UNCY a buy, hold, or sell?
Analysts rate UNCY a Buy, with a price target of $22.00 (+357.4% vs the current price). Our ST Score grades it C (40.5/100). The ST Score is a data-driven signal, not a recommendation.
What are UNCY's factor grades?
Valuation B+, Profitability C-, Financial Strength C+, Momentum C-, Growth C, Forecast A, Sentiment F.
What is UNCY's valuation grade?
Unicycive Therapeutics, Inc. (UNCY) earns a valuation grade of B+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is UNCY's growth grade?
Unicycive Therapeutics, Inc. (UNCY) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is UNCY's profitability grade?
Unicycive Therapeutics, Inc. (UNCY) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is UNCY's financial strength grade?
Unicycive Therapeutics, Inc. (UNCY) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for UNCY?
The average analyst price target for Unicycive Therapeutics, Inc. (UNCY) is $22.00 from 8 analysts, which is +357.4% versus the recent price of $4.81.
What is UNCY's Piotroski score?
Unicycive Therapeutics, Inc. (UNCY) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.